Nuveen Asset Management, LLC Autolus Therapeutics PLC Transaction History

Nuveen Asset Management, LLC

  • $345 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 14, 2019
SELL
$24.38 - $34.71 $689,149 - $981,147
-28,267 Closed
0 $0
Q4 2018

Feb 14, 2019
SELL
$24.21 - $48.01 $266,527 - $528,542
-11,009 Reduced 28.03%
28,267 $928,000
Q3 2018

Nov 13, 2018
BUY
$20.86 - $33.33 $171,364 - $273,805
8,215 Added 26.45%
39,276 $1.21 Million
Q2 2018

Aug 14, 2018
BUY
$25.0 - $27.75 $776,525 - $861,942
31,061 New
31,061 $832,000

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email